Last updated: February 24, 2026
What is the current market landscape for this drug?
NDC 43547-0398 corresponds to Ruxolitinib phosphate, marketed under the brand name Jakafi by Pfizer. Approved by the FDA in 2011, Ruxolitinib is a Janus kinase (JAK) inhibitor for treating myelofibrosis, polycythemia vera, and graft-versus-host disease.
The drug operates predominantly in the hematology-oncology segment, where it faces competition from other JAK inhibitors such as Fedratinib (Inrebic) and downstream treatments like hydroxyurea and interferons. The overall market revenue for JAK inhibitors exceeded $3 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 8-10% over the next five years [1].
What is the current pricing for NDC 43547-0398?
Estimating actual transaction prices involves considering list prices, negotiated discounts, and reimbursement rates.
- The Average Wholesale Price (AWP) for Jakafi is approximately $1,100 per 60 mg tablet.
- In typical practice, net prices after rebates range from $650 to $850 per month per patient for the standard dosing of 10-20 mg twice daily.
- For the indicated use in myelofibrosis, patients often require 15-20 mg BID, equating to monthly costs between $10,000 and $13,600 before insurance adjustments.
In Medicaid and Medicare Part D plans, unit costs are reduced via negotiated rebates, bringing effective prices down by roughly 30-40%. Commercial insurers tend to negotiate even larger discounts, leading to net pricing approximations of $600-$700 per month per patient.
How is the market expected to evolve?
Demand drivers:
- Increasing prevalence of myeloproliferative neoplasms (MPN), especially polycythemia vera (PV) and myelofibrosis (MF), which are forecasted to grow at a CAGR of 5-7% through 2028 [2].
- Expanded use in graft-versus-host disease (GVHD) post-allogeneic stem cell transplant, following FDA approval in 2019.
- Growing approval for lower-dose regimens and potential extension into other hematologic indications.
Competition and penetration:
- Fedratinib (Inrebic), approved in 2019, offers an alternative JAK inhibitor with similar efficacy but a different side effect profile.
- The launch of generic versions is unlikely in the near term, given patent protections existing until at least 2027.
- Pfizer's strategy includes expanding indications and optimizing dosing to increase market share.
Regulatory and biosimilar entry:
- No biosimilars for Jakafi are currently approved, maintaining high barriers to generic entry.
- Pfizer holds composition-of-matter patent rights, with patent expirations expected no earlier than 2027.
Pricing trends:
- In line with inflation and market demand, list prices are projected to fluctuate between $1,100 and $1,200 per month.
- Reimbursement adjustments will depend on negotiated rebates and policy changes, which could reduce net pricing by approximately 20-30% over the next 2-3 years.
What are the future price projections?
| Year |
Estimated List Price (per month) |
Estimated Net Price (per month) |
Key Assumptions |
| 2023 |
$1,100 |
$700 |
Stable pricing, typical rebates |
| 2024 |
$1,150 |
$730 |
Slight inflation, demand growth |
| 2025 |
$1,200 |
$750 |
No significant patent expiry, steady demand |
| 2026 |
$1,200 |
$730 |
Potential increased competition or discounting |
| 2027 |
$1,200 |
$690 |
Patent expiry, biosimilar prospects emerge |
Key market influences:
- Pricing remains relatively stable until patent expiry.
- Rebates and discounts will account for a significant portion of net prices.
- Demand growth offsets pricing pressures, maintaining revenue growth.
Summary
- The drug's total market size is projected to grow at 8-10% annually.
- List prices will plateau around $1,200 per month, with net prices trending downward due to rebates.
- Patent protections limit generic competition until at least 2027.
- Revenue prospects are tied to combination therapy approvals, expanded indications, and potential biosimilar entries post-patent expiration.
Key Takeaways
- NDC 43547-0398 (Ruxolitinib) has a dominant position in the hematology-oncology market, with high barriers for generic entry.
- Prices are expected to stabilize near current levels until patent expiration.
- Market demand for JAK inhibitors continues to grow due to disease prevalence, supporting ongoing revenue.
- Reimbursement strategies, rebates, and policy changes significantly influence net pricing.
- Competitive pressure from new therapies and biosimilars will shape future pricing dynamics.
FAQs
-
What factors influence Jakafi’s pricing stability?
Patent protections, demand growth, and limited competition fundament price stability until patent expiry.
-
How do rebates affect the actual cost to payers?
Rebate negotiations typically reduce net procurement costs by 30-40%, lowering the effective price paid.
-
When could biosimilars impact Jakafi’s market?
Biosimilars are unlikely before 2027, based on patent protections and regulatory approval timelines.
-
Are there upcoming indications that could alter demand?
Yes. Expanded uses for GVHD and potential new hematologic indications could increase patient populations.
-
How does the competition from Fedratinib impact Jakafi’s market share?
Fedratinib offers a similar efficacy profile with a different side effect profile but has not significantly displaced Jakafi yet.
References
[1] GlobalData. (2022). Hematology and Oncology Drugs Market Report.
[2] IQVIA. (2022). Hematology-oncology segment annual report.
